Hetero gets DCGI nod for molnupiravir to treat high-risk Covid-19 patients
Hyderabad: Hyderabad-based Hetero, a vertically integrated pharmaceutical organisation, has received Drug Controller General of India (DCGI) nod for manufacture and marketing of molnupiravir capsules 200 mg (Movfor). Molnupiravir is an oral antiviral indicated for restricted emergency use in India to treat adult patients with Covid-19. Hetero’s Movfor will be made available in a 40 capsule […]
Hyderabad: Hyderabad-based Hetero, a vertically integrated pharmaceutical organisation, has received Drug Controller General of India (DCGI) nod for manufacture and marketing of molnupiravir capsules 200 mg (Movfor).
Molnupiravir is an oral antiviral indicated for restricted emergency use in India to treat adult patients with Covid-19.
Hetero’s Movfor will be made available in a 40 capsule pack (200 mg per capsule) and will be marketed by its associate company ‘Hetero Healthcare’ in India with the support of its distribution network across the country.
Dr B Partha Saradhi Reddy, chairman, Hetero Group of Companies, said, “This approval consolidates India’s efforts to address the world’s greatest health threats, i.e., Covid-19. Improving access to critical medicines will always remain the highest of priorities to us.”
The commercial production of Movfor will be undertaken at Hetero’s facilities in Telangana and Himachal Pradesh.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
